| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Phe-Met-Arg-Phe Like Peptide targets FMRFamide-related peptide (FaRP) receptors, which are G protein-coupled receptors involved in neuromodulation and cellular communication. As a FMRF-like peptide, it mimics the actions of endogenous FMRFamide, a neuropeptide that regulates various physiological processes in invertebrates, including muscle contraction and neuronal excitability.
|
|---|---|
| ln Vitro |
In vitro, this peptide acts as a FMRF-like neuropeptide, facilitating interactions within biological systems. Its activity is assessed using receptor binding assays and functional assays measuring its effects on muscle contraction, neuronal signaling, or calcium flux in snail or other invertebrate preparations.
|
| ln Vivo |
In vivo activity data for this peptide are limited in the available literature. As a research peptide, its primary application is in in vitro studies of neuropeptide signaling. Its effects on muscle contraction and neuronal excitability in snails have been characterized, but systematic in vivo studies in other models are lacking.
|
| Enzyme Assay |
In vitro receptor binding assays for this peptide are performed using membrane preparations from snail tissues expressing FMRFamide receptors. Radioligand competition binding assays are used to measure the peptide's affinity for these receptors. Functional assays measure the peptide's ability to activate receptor-mediated signaling pathways, such as calcium mobilization or cAMP modulation.
|
| Cell Assay |
In vitro cellular assays for this peptide are performed using snail muscle or neuronal preparations. Tissues are treated with the peptide, and its effects on muscle contraction, neuronal firing, or second messenger levels are measured. These assays provide functional evidence of the peptide's neuropeptide activity.
|
| Animal Protocol |
In vivo animal experiments for this peptide are not extensively documented. As a research peptide derived from snail, its use is primarily limited to in vitro applications in invertebrate models. For in vivo studies in other organisms, appropriate models and administration routes would need to be established.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of this peptide have not been systematically characterized. The peptide has a molecular weight of 904.02 and is supplied as a research compound with a purity of 99.50%. It should be stored appropriately to maintain stability. Further PK studies are not applicable as the compound is used in research rather than therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for this peptide are not extensively reported. As a research-use peptide, its safety profile has not been formally evaluated in comprehensive toxicology studies. The compound is intended for research purposes only. Standard laboratory safety precautions should be followed when handling this peptide.
|
| References | |
| Additional Infomation |
Phe-Met-Arg-Phe Like Peptide, Snail Helix aspersa is a FMRF-like neuropeptide from the visceral and somatic muscles of the snail Helix aspersa. FMRF (Phe-Met-Arg-Phe) is a neuropeptide consisting of four amino acid residues. This product is for research use only.
|
| Molecular Formula |
C44H61N11O10
|
|---|---|
| Molecular Weight |
904.022840000001
|
| Exact Mass |
903.46
|
| CAS # |
98495-35-3
|
| PubChem CID |
3035766
|
| Appearance |
White to off-white solid powder
|
| Density |
1.43g/cm3
|
| Index of Refraction |
1.667
|
| LogP |
2.547
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
24
|
| Heavy Atom Count |
65
|
| Complexity |
1730
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@@H]4CCC(=O)N4
|
| InChi Key |
CLWGEQPXAKIVMA-NXBWRCJVSA-N
|
| InChi Code |
InChI=1S/C44H61N11O10/c1-25(2)21-31(40(62)50-28(15-9-19-48-44(46)47)38(60)51-30(37(45)59)22-26-11-5-3-6-12-26)52-41(63)32(23-27-13-7-4-8-14-27)53-42(64)34-16-10-20-55(34)43(65)33(24-36(57)58)54-39(61)29-17-18-35(56)49-29/h3-8,11-14,25,28-34H,9-10,15-24H2,1-2H3,(H2,45,59)(H,49,56)(H,50,62)(H,51,60)(H,52,63)(H,53,64)(H,54,61)(H,57,58)(H4,46,47,48)/t28-,29-,30-,31-,32-,33-,34-/m0/s1
|
| Chemical Name |
(3S)-4-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-oxo-3-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]butanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1062 mL | 5.5309 mL | 11.0617 mL | |
| 5 mM | 0.2212 mL | 1.1062 mL | 2.2123 mL | |
| 10 mM | 0.1106 mL | 0.5531 mL | 1.1062 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
